By signing the Copyright Letter the authors retain the rights of self-archiving. Following are the important features of self-archiving policy of Bentham Science journals:
Authors can deposit the first draft of a submitted article on their personal websites, their institution’s repositories or any non-commercial repository for personal use, internal institutional use or for permitted scholarly posting.
Authors may deposit the ACCEPTED VERSION of the peer-reviewed article on their personal websites, their institution’s repository or any non-commercial repository such as PMC, arXiv after 12 MONTHS of publication on the journal website. In addition, an acknowledgement must be given to the original source of publication and a link should be inserted to the published article on the journal's/publisher’s website.
If the research is funded by NIH, Wellcome Trust or any other Open Access Mandate, authors are allowed the archiving of published version of manuscripts in an institutional repository after the mandatory embargo period. Authors should first contact the Editorial Office of the journal for information about depositing a copy of the manuscript to a repository. Consistent with the copyright agreement, Bentham Science does not allow archiving of FINAL PUBLISHED VERSION of manuscripts.
The link to the original source of publication should be provided by inserting the DOI number of the article in the following sentence: “The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/openurl/content.php?genre=article&doi=[insert DOI].”
There is no embargo on the archiving of articles published under the OPEN ACCESS PLUS category. Authors are allowed deposition of such articles on institutional, non-commercial repositories and personal websites immediately after publication on the journal website.
LONG-TERM ARCHIVING OF BENTHAM SCIENCE CONTENT
To ensure permanent access to our publications, Bentham Science has an agreement with Portico to have a long-term preservation of the content published in its journals.
Ijeoma F. Uchegbu Department of Pharmaceutics University of London London (UK) Biography
Biography of Ijeoma F. Uchegbu
Ijeoma Uchegbu is Professor of Pharmaceutical Nanoscience at the UCL School of Pharmacy, University College London (UCL), Pro-Vice Provost for Africa and the Middle East, UCL and Chief Scientific Officer of Nanomerics. She obtained her PhD from the School of Pharmacy, University of London in 1994. In 2015, Ijeoma became UCL’s Pro-Vice Provost for Africa and The Middle East. Nanomerics was founded in 2010 by Ijeoma and Andreas G. Schätzlein. Nanomerics is a specialtiy pharmaceutical company focused on exploiting pharmaceutical nanotechnology platforms for medicines development. Ijeoma has been awarded various prizes for her work, notably the UK Department for Business Innovation Skills’ Women of Outstanding Achievement in Science Engineering and Technology award and the Royal Pharmaceutical Society’s Pharmaceutical Scientist of the Year 2012. Ijeoma was elected to the Controlled Release Society College of Fellows in 2013 and became an Eminent Fellow of the Academy of Pharmaceutical Sciences in 2013.